课题基金 / 基金详情

Development of a novel surgical implant to treat pelvic organ prolapse using advanced materials

Development of a novel surgical implant to treat pelvic organ prolapse using advanced materials
使用先进材料开发新型手术植入物来治疗盆腔器官脱垂
批准号:
10072069
负责人:
金额:
$6.28万
依托单位:
依托单位国家:
英国
项目类别:
Collaborative R&D
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
盆腔器官脱垂(POP)是一种常见的疾病,是由盆底薄弱引起的阴道内部器官的膨出,随着年龄和分娩而加剧。聚丙烯材料制成的网片以前用于手术治疗POP。由于越来越多的担忧,这种材料在骨盆中会引起慢性疼痛、继发于持续性感染的慢性炎症以及网状物收缩导致的纤维瘢痕,因此已被禁止使用。**目前的选择:** POP的管理包括观察等待或插入硅基托托来支撑突出的器官,通常因不适而停止。没有植入物的手术导致超过三分之一的病例复发。目前,临床需求未得到满足,没有具有竞争力的替代品来替代聚丙烯网片。**解决方案:** Hastalex(r)是我们公司开发的一种贸易注册的石墨烯基材料。该材料已获得专利,并且没有现有的知识产权侵犯我们的自由操作(由Stratagem IPM Ltd, Cambridge执行)。由于其新颖的配方,Hastalex利用了石墨烯的优越性能。材料的机械强度和弹性已经调整到与骨盆组织的特性相匹配。Hastalex及其生物可降解版本BioHastalex(r)的其他应用包括心脏瓣膜、肌腱、人工尿道括约肌,以及作为卫生棉条样的药物输送装置。2022年青年创新者奖为我提供了支持和资金,以开展Hastalex的体外和体内毒理学研究,证明它无毒且具有生物相容性。我一直在与NanoRegMed合作,与伦敦帝国理工学院合作,设计一种用于脱垂手术的新型植入物。**当前建议:**本建议的目的是进一步发展盆腔植入物。第一步包括设计和制造,通过两种制造方法进行比较。1)平面Hastalex板材,使用激光技术切割图案。2)公司最新开发的Hastalex纤维针织膜。这两种产品将在临床前动物试验中评估治疗效果。我将与监管机构建立联系,勾勒出临床可行性研究的路径。该项目的愿景是通过内部制造或通过大型医疗设备公司的支持,在POP手术中实现膜。我们的成功将对英国经济产生重大的积极影响。材料和制造都是环保的。
英文摘要
Pelvic organ prolapse (POP), a common condition, is the bulging of internal organs down the vaginal canal secondary to weaknesses in the pelvic floor, exacerbated by age and childbirth. A mesh made of polypropylene material was previously used for the surgical management of POP. It has since been banned due to rising concerns that, in the pelvis, the material causes symptoms of chronic pain, chronic inflammation secondary to persistent infection, and fibrous scarring as a result of mesh shrinkage.**Current options:** Management of POP includes watchful waiting or the insertion of a silicone-based pessary to hold up protruding organs, often discontinued due to discomfort. Surgery without an implant results in recurrence in over a third of cases. Currently, there is an unmet clinical need with no competitive alternative to the polypropylene mesh.**Solution:** Hastalex(r) is a trade registered graphene-based material, developed by our company. The material has been patented and with no existing intellectual property that infringes our Freedom to Operate (carried out by Stratagem IPM Ltd, Cambridge). Hastalex harnesses the superior properties of graphene due to its novel formulation. The mechanical strength and elasticity of the material have been tuned to match the properties of pelvic tissue. Other applications of Hastalex, and the biodegradable version BioHastalex(r), include heart valves, tendons, artificial urinary sphincters, and as a tampon-like drug delivery device.The Young Innovator award 2022 provided me with the support and funding to carry out in vitro and in vivo toxicology studies on Hastalex proving it to be non-toxic and biocompatible. I have been working with NanoRegMed, in collaboration with Imperial College London, on the design of a novel implant to be used in prolapse surgery.**Current Proposal:** The aim of this proposal is to further the development of the pelvic implant. The first step includes design and manufacturing via two fabrication methodologies for comparison. 1) Flat Hastalex sheet with patterns cut using laser technology. 2) Knitted membrane with Hastalex fibres, developed recently by the company. Both products will be assessed for treatment efficacy at preclinical animal trials.I will establish contacts with regulatory bodies to sketch the pathway toward clinical feasibility studies. The vision of this project is to implement the membrane in POP surgery with manufacturing either in-house or via the support of a larger medical devices company. Our success would have a major positive impact on the UK economy. The materials and manufacturing are environmentally friendly.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: